Anne Marie Cook, general counsel of the Camden, Massachusetts-based biopharmaceutical firm Sage Therapeutics for nine years, will step down at the end of this month, part of a massive cost-reduction plan imposed after studies dashed its hopes of marketing the drug dalzanemdor to treat Parkinson's and Alzheimer's diseases, according to an Aug. 14 government filing.